Petros Pharmaceuticals, Inc. Preferred Stock Dividends, Income Statement Impact
Petros Pharmaceuticals, Inc. (PTPI) reported Preferred Stock Dividends, Income Statement Impact of $232.70 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2026-08-13
- Petros Pharmaceuticals, Inc. preferred stock dividends, income statement impact for the quarter ending 2026-06-30 was $232.70K, a 6.65% increase year-over-year.
- Petros Pharmaceuticals, Inc. preferred stock dividends, income statement impact for the quarter ending 2026-03-31 was $232.82K, a 15.39% decline year-over-year.
- Petros Pharmaceuticals, Inc. preferred stock dividends, income statement impact for the quarter ending 2025-12-31 was $249.42K, a 43.84% decline year-over-year.
- Petros Pharmaceuticals, Inc. preferred stock dividends, income statement impact for the quarter ending 2025-09-30 was $231.21K, a 78.02% decline year-over-year.
- Petros Pharmaceuticals, Inc. preferred stock dividends, income statement impact for fiscal 2025 was $973.98K, a 57.80% decline from fiscal 2024.
- Petros Pharmaceuticals, Inc. preferred stock dividends, income statement impact for fiscal 2024 was $2.31M, a 180.98% increase from fiscal 2023.
- Petros Pharmaceuticals, Inc. preferred stock dividends, income statement impact for fiscal 2023 was $821.46K.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2026-06-30 | $232.70K 10-Q · filed 2026-08-13 | $465.52K 10-Q · filed 2026-08-13 | $714.94K derived: sum of 3 quarters · filed 2026-08-13 | $946.15K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $232.82K 10-Q · filed 2026-05-13 | $482.24K derived: sum of 2 quarters · filed 2026-05-13 | $713.45K derived: sum of 3 quarters · filed 2026-05-13 | $931.64K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $249.42K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $480.63K derived: sum of 2 quarters · filed 2026-04-15 | $698.82K derived: sum of 3 quarters · filed 2026-08-13 | $973.98K 10-K · filed 2026-04-15 |
| 2025-09-30 | $231.21K 10-Q · filed 2025-11-13 | $449.40K derived: sum of 2 quarters · filed 2026-08-13 | $724.57K 10-Q · filed 2025-11-13 | $1.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $218.19K 10-Q · filed 2026-08-13 | $493.36K 10-Q · filed 2026-08-13 | $937.48K derived: sum of 3 quarters · filed 2026-08-13 | $1.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $275.17K 10-Q · filed 2026-05-13 | $719.29K derived: sum of 2 quarters · filed 2026-05-13 | $1.77M derived: sum of 3 quarters · filed 2026-05-13 | $1.99M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $444.12K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $1.50M derived: sum of 2 quarters · filed 2026-04-15 | $1.71M derived: sum of 3 quarters · filed 2026-04-15 | $2.31M 10-K · filed 2026-04-15 |
| 2024-09-30 | $1.05M 10-Q · filed 2025-11-13 | $1.27M derived: sum of 2 quarters · filed 2025-11-13 | $1.86M 10-Q · filed 2025-11-13 | $2.35M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $216.80K 10-Q · filed 2025-08-14 | $812.30K 10-Q · filed 2025-08-14 | $1.29M derived: sum of 3 quarters · filed 2025-08-14 | $1.63M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $595.50K 10-Q · filed 2025-05-15 | $1.08M derived: sum of 2 quarters · filed 2025-05-15 | $1.42M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $482.22K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $821.46K derived: sum of 2 quarters · filed 2025-03-31 | $821.46K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $339.23K 10-Q · filed 2024-11-13 | $339.23K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |